Zai Lab Ltd (ZLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zai Lab Ltd (ZLAB) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.04 Million) by net assets ($759.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zai Lab Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Zai Lab Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Zai Lab Ltd for a breakdown of total debt and financial obligations.
Zai Lab Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zai Lab Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
|
BW LPG Limited
F:BW9
|
0.094x |
|
Wuhan PS Information Tech
SHE:300184
|
0.011x |
|
ePlus inc
NASDAQ:PLUS
|
-0.082x |
|
Shell plc
LSE:SHEL
|
0.050x |
|
Comet Holding AG
SW:COTN
|
0.038x |
|
EMEIS SA
PA:EMEIS
|
0.037x |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
0.016x |
Annual Cash Flow Conversion Efficiency for Zai Lab Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Zai Lab Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Zai Lab Ltd (ZLAB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $840.90 Million | $-214.87 Million | -0.256x | -2.65% |
| 2023-12-31 | $796.12 Million | $-198.18 Million | -0.249x | +29.20% |
| 2022-12-31 | $1.05 Billion | $-367.64 Million | -0.352x | +11.66% |
| 2021-12-31 | $1.38 Billion | $-549.23 Million | -0.398x | -115.41% |
| 2020-12-31 | $1.17 Billion | $-216.06 Million | -0.185x | +71.50% |
| 2019-12-31 | $294.66 Million | $-191.01 Million | -0.648x | -66.87% |
| 2018-12-31 | $251.08 Million | $-97.54 Million | -0.388x | -182.25% |
| 2017-12-31 | $235.17 Million | $-32.37 Million | -0.138x | -122.06% |
| 2016-12-31 | $-51.55 Million | $-32.16 Million | 0.624x | -0.05% |
| 2015-12-31 | $-18.37 Million | $-11.46 Million | 0.624x | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more